researchdrivelogo.jpg
Global Cancer Stem Cells Market to Surpass $1,898.3 Million, Growing with a CAGR of 11.8% from 2019 to 2026, Post-COVID-19 Disaster by Research Dive
17 août 2021 09h02 HE | Research Dive
New York, USA, Aug. 17, 2021 (GLOBE NEWSWIRE) -- A newest report on the global cancer stem cells market has been added by Research Dive to its repository. The report presents exhaustive insights on...
researchdrivelogo.jpg
Global Cancer Stem Cells Market to Witness Exponential Growth Owing to the Rising Efficiency of Stem Cell Therapy – Informative Report [180 Pages] by Research Dive
02 août 2021 09h00 HE | Research Dive
New York, USA, Aug. 02, 2021 (GLOBE NEWSWIRE) -- A recently published report by Research Dive states that the global cancer stem cells market is expected to witness a rise in revenue from $786.3...
erytech.jpg
ERYTECH Achieves Milestones in TRYbeCA1 Phase 3 Trial of Eryaspase in Second-line Pancreatic Cancer
04 nov. 2019 01h30 HE | Erytech Pharma S.A.
Trial opened for patient enrollment in the United States Independent Data Monitoring Committee recommends continuation of the trial as planned LYON, France and CAMBRIDGE, Mass., Nov. 04, 2019 ...
erytech.jpg
ERYTECH Announces Enrollment of First Patients in Phase 3 Clinical Trial Evaluating Eryaspase for the Treatment of Second Line Pancreatic Cancer
20 sept. 2018 01h30 HE | Erytech Pharma S.A.
LYON, France and CAMBRIDGE, Mass., Sept. 20, 2018 (GLOBE NEWSWIRE) -- ERYTECH Pharma (Euronext Paris: ERYP - Nasdaq: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies...
erytech.jpg
ERYTECH annonce le recrutement des premiers patients dans son étude clinique de Phase 3 avec eryaspase pour le traitement en seconde ligne du cancer du pancréas
20 sept. 2018 01h30 HE | Erytech Pharma S.A.
LYON, France et CAMBRIDGE, Mass., 20 sept. 2018 (GLOBE NEWSWIRE) -- ERYTECH Pharma (Euronext Paris: ERYP - Nasdaq: ERYP), société biopharmaceutique de stade clinique qui développe des thérapies...
erytech.jpg
ERYTECH Reports First Half of 2018 Financial Results and Provides Business Update
10 sept. 2018 16h30 HE | Erytech Pharma S.A.
Conference call and webcast scheduled for Tuesday, September 11that 2:30 pm CET/8:30 am EDT Strategic shift to development of eryaspase for solid tumors confirmedPhase 3 trial for eryaspase in second...
erytech.jpg
ERYTECH publie ses résultats financiers et fait le point sur ses activités du premier semestre 2018
10 sept. 2018 16h30 HE | Erytech Pharma S.A.
Conférence téléphonique et webcast : mardi 11 septembre à 14h30 Confirmation du virage stratégique entrepris vers le développement d’eryaspase dans les tumeurs solidesLancement de l’étude de Phase...
erytech.jpg
ERYTECH to Host Second Quarter 2018 Conference Call and Business Update
06 sept. 2018 01h30 HE | Erytech Pharma S.A.
LYON, France, Sept. 06, 2018 (GLOBE NEWSWIRE) -- ERYTECH Pharma (Euronext Paris: ERYP - Nasdaq: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating...
erytech.jpg
ERYTECH tiendra un webcast le 11 septembre 2018 à l’occasion de ses résultats semestriels 2018
06 sept. 2018 01h30 HE | Erytech Pharma S.A.
LYON, France, 06 sept. 2018 (GLOBE NEWSWIRE) -- ERYTECH Pharma (Euronext Paris et Nasdaq : ERYP), société biopharmaceutique de stade clinique qui développe des thérapies innovantes en encapsulant...
erytech.jpg
ERYTECH to Present Preclinical and Clinical Data on Use of Eryaspase in ALL and AML at EHA 2018
15 juin 2018 01h30 HE | Erytech Pharma S.A.
LYON, France, June 15, 2018 (GLOBE NEWSWIRE) -- ERYTECH Pharma (Euronext:ERYP) (Nasdaq:ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic...